Joel Myers
About Joel Myers
Joel Myers is the Executive Director of Immunology & Fibrosis Worldwide Medical at Bristol Myers Squibb in Princeton, New Jersey.
Company
Joel Myers currently works at Bristol Myers Squibb, a globally recognized biopharmaceutical company. He holds the position of Executive Director, Immunology & Fibrosis Worldwide Medical, based in Princeton, New Jersey, United States. Bristol Myers Squibb focuses on developing innovative medicines across a variety of disease areas to address unmet medical needs.
Current Title and Role
Joel Myers serves as the Executive Director, Immunology & Fibrosis Worldwide Medical at Bristol Myers Squibb. In this role, he is responsible for leading the development and implementation of medical strategies on a global scale for immunology and fibrotic diseases. His work involves close collaboration with various departments to define and execute both development and commercialization strategies for investigational medicines.
Professional Background and Experience
Joel Myers has a robust professional background, predominantly at Bristol Myers Squibb. His career includes multiple leadership positions, such as Senior Director, Head of Fibrosis Worldwide Medical (2020-2021), Director, Global Medical Lead Fibrosis (2017-2020), and Associate Director roles focusing on HIV, both in the US and Europe. He also has significant experience working in the NHS system in the UK, holding various specialist positions in pharmacy and clinical pharmacology.
Education and Expertise
Joel Myers holds an MPharm from the University of Bath and an IPresc from King's College London, along with a PGDipGPP from UCL. His educational background in pharmacy has laid a strong foundation for his expertise in medical strategies and leadership in the biopharmaceutical industry. These qualifications have enabled him to successfully lead teams and projects across various therapeutic areas, including virology, immunology, and fibrotic diseases.
Key Projects and Strategic Initiatives
Joel Myers has played pivotal roles in advancing investigational medicines for conditions such as eosinophilic esophagitis (EoE) and other eosinophilic gastrointestinal disorders (EGIDs) from research stages to clinical trials. He has also been instrumental in defining biomarker strategies for type 2 inflammatory and fibrotic diseases. His work often involves leading cross-functional global teams to develop comprehensive disease strategies for conditions like atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), and liver cirrhosis.